Related Experiment Video
Updated: Feb 2, 2026

Concurrent Quantification of Cellular and Extracellular Components of Biofilms
Published on: December 10, 2013
Gastric perforation related to concurrent use of nintedanib and ramucirumab
Saeko Takahashi1, Saori Murata1, Yudai Yoshino2
1Department of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan.
Abstract:
The prevalence of lung cancer in idiopathic pulmonary fibrosis (IPF) patients ranges from 9.8 to 38%. Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), has been approved for IPF after phase III INPULSIS trials in 2014. Ramucirumab, a monoclonal antibody for VEGFR-2, combined with docetaxcel, has been approved for advanced non-small cell lung cancer (NSCLC) after the phase III REVEL trail in 2014. Physicians will have more IPF patients being treated with nintedanib, who subsequently develop NSCLC, and therefore will likely be treated with ramucirumab plus docetaxel. We report the first case of 70-year-old man taking nintedanib for his IPF and treated with ramucirumab plus docetaxel as a seventh-line therapy for his pulmonary adenocarcinoma. On day 15 of his chemotherapy treatment cycle 2, after taking nintedanib for nine days, he developed gastric perforation.
Insights
Idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib may develop lung cancer. A case report details a patient experiencing gastric perforation after receiving ramucirumab plus docetaxel for non-small cell lung cancer while on nintedanib.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) affects 9.8–38% of patients with lung cancer.
- Nintedanib, a tyrosine kinase inhibitor (TKI), is approved for IPF.
- Ramucirumab plus docetaxel is approved for advanced non-small cell lung cancer (NSCLC).
Observation:
- A 70-year-old man with IPF was treated with nintedanib.
- He later developed pulmonary adenocarcinoma and received ramucirumab plus docetaxel as seventh-line therapy.
- He experienced gastric perforation during his second chemotherapy cycle.
Findings:
- This case highlights a potential drug interaction between nintedanib and ramucirumab plus docetaxel.
- The patient developed gastric perforation after concurrent treatment.
Implications:
- Physicians should be aware of the potential for severe adverse events when treating IPF patients with nintedanib who subsequently require chemotherapy for NSCLC.
- Further research is needed to understand and manage this drug interaction.
- This case underscores the importance of vigilant patient monitoring during combination cancer therapies.
Related Concept Videos
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Gastric Phase of Digestion
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
Neural Regulation

